Finance

Lists
Q3 2026 earnings • released • Revenue beat +0.62%
See results
BAYN:ETR
Bayer AG
€56.22
+3.65%
(+1.98) 1D
Nov 5, 5:38:41 PM GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for BAYN...
Open
€55.00
High
€56.60
Low
€55.00
Mkt. cap
54.64B
Avg. vol.
2.53M
Volume
4.90M
Dividend
0.20%
Quarterly dividend
€0.03
Ex-dividend date
Apr 27, 2026
52-wk high
€56.60
52-wk low
€25.78
EPS
-€1.77
Shares outstanding
982.42M
No. of employees
88K
Open
€55.00
High
€56.60
Low
€55.00
Mkt. cap
54.64B
Avg. vol.
2.53M
Volume
4.90M
Dividend
0.20%
Quarterly dividend
€0.03
Ex-dividend date
Apr 27, 2026
52-wk high
€56.60
52-wk low
€25.78
EPS
-€1.77
Shares outstanding
982.42M
No. of employees
88K
News stories
From web sources and news partners
Profile
Bayer AG is a German multinational pharmaceutical and biotechnology company and is one of the largest pharmaceutical companies and biomedical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include pharmaceuticals, consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The company is a component of the EURO STOXX 50 stock market index. Bayer was founded in 1863 in Barmen as a partnership between dye salesman Friedrich Bayer and dyer Johann Friedrich Weskott. The company was established as a dyestuffs producer, but the versatility of aniline chemistry led Bayer to expand its business into other areas. In 1899, Bayer launched the compound acetylsalicylic acid under the trademarked name Aspirin. Aspirin is on the World Health Organization's List of Essential Medicines. In 2021, it was the 34th most commonly prescribed medication in the United States, with more than 17 million prescriptions. In 1904, Bayer received a trademark for the "Bayer Cross" logo, which was, from 1910, subsequently stamped onto each aspirin tablet, creating an enduring brand image. Wikipedia
About Bayer AG
CEOBill Anderson
Employees87.8K
FoundedAug 1, 1863
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitebayer.com
Last report
Nov 3, 2026
Fiscal period
Q3 2026
- / €0.28
Revenue / Est. (EUR)
10.05B / 9.99B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
9.66B
11.44B
13.40B
10.87B
Cost of goods sold
4.31B
4.23B
5.23B
4.52B
Cost of revenue
4.31B
4.23B
5.23B
4.52B
Research and development expenses
1.50B
1.29B
1.42B
1.51B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.40B
5.37B
3.70B
3.94B
Operating expense
5.90B
3.89B
4.64B
5.35B
Total operating expenses
10.20B
8.12B
9.88B
9.87B
Operating income
-543.00M
3.32B
3.53B
999.00M
Other non operating income
-7.00M
1.51B
-55.00M
-329.00M
EBT including unusual items
-1.16B
-3.37B
2.99B
321.00M
EBT excluding unusual items
-1.16B
4.63B
2.99B
502.00M
Income tax expense
-202.00M
378.00M
222.00M
92.00M
Effective tax rate
17.40%
-11.21%
7.43%
28.66%
Other operating expenses
993.00M
-2.76B
-470.00M
-97.00M
Net income
-963.00M
-3.76B
2.76B
219.00M
Net profit margin
-9.97%
-32.85%
20.61%
2.01%
Earnings per share
0.57
-
-
-
Interest and investment income
-
471.00M
-
-
Interest expense
-539.00M
-527.00M
-474.00M
-81.00M
Net interest expenses
-539.00M
-56.00M
-474.00M
-81.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
412.00M
4.72B
4.76B
2.16B
Gain or loss from assets sale
-33.00M
-191.00M
-161.00M
-14.00M
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps